Patents Assigned to Daiichi Pharmaceutical Co., LTD
-
Publication number: 20040132756Abstract: A solid preparation improved in oral absorption and reduced in fluctuations of oral absorption can be obtained by incorporating an organic acid, particularly tartaric acid, in a solid preparation having, as an active ingredient, a high content of a quinolone compound, particularly sitafloxacin, having poor water solubility at pH around neutrality.Type: ApplicationFiled: December 19, 2003Publication date: July 8, 2004Applicant: DAIICHI PHARMACEUTICAL CO., LTD.Inventors: Katsuo Kataoka, Hiroshi Kikuchi, Tatsuya Suzuki, Takahiro Shimaya, Hideo Kobayashi, Akira Kurosawa, Koichi Ishido
-
Publication number: 20040127705Abstract: A pyrrolesulfonamide derivative having the following formula (I): 1Type: ApplicationFiled: July 10, 2003Publication date: July 1, 2004Applicant: DAIICHI PHARMACEUTICAL CO., LTD.Inventors: Akira Mizuno, Makoto Shibata, Tomoe Kamei, Harukazu Fukami, Norio Inomata
-
Patent number: 6756378Abstract: Compounds that selectively inhibit the binding of ligands to &agr;4&bgr;1 integrin (VLA-4) and methods for their preparation are disclosed. In one embodiment, compounds of the invention are represented by Formula I: As selective inhibitors of VLA-4 mediated cell adhesion, compounds of the present invention are useful in the treatment of conditions associated with such adhesion, including, but not limited to, such conditions as inflammatory and autoimmune responses, diabetes, asthma, psoriasis, inflammatory bowel disease, transplantation rejection, and tumor metastasis. Also disclosed are pharmaceutical compositions, methods of inhibiting VLA-4 mediated cell adhesion and methods of treating conditions associated with LA-4 mediated cell adhesion, which involve compounds of Formula I.Type: GrantFiled: December 28, 2001Date of Patent: June 29, 2004Assignees: Pharmacopeia Drug Discovery, Inc., Daiichi Pharmaceutical Co., Ltd.Inventors: John J. Baldwin, Edward McDonald, Kevin Joseph Moriarty, Christopher Ronald Sarko, Nobuo Machinaga, Atsushi Nakayama, Jun Chiba, Shin Iimura, Yoshiyuki Yoneda
-
Publication number: 20040121398Abstract: The present invention relates to a method for predicting whether a protein or polypeptide (B) interacts with a specific protein or polypeptide (A), wherein the method comprises the steps of:Type: ApplicationFiled: September 10, 2002Publication date: June 24, 2004Applicants: DAIICHI PHARMACEUTICAL CO., LTD., FUJITSU LIMITEDInventors: Hirofumi Doi, Atsushi Suzuki
-
Patent number: 6747023Abstract: Described in the present invention are a sulfonyl derivative represented by the following formula (I): Q1—Q2—T1—Q3—SO2—QA (I) [wherein Q1 represents a saturated or unsaturated 5- or 6-membered cyclic hydrocarbon group, 5- or 6-membered heterocyclic group, dicyclic fused ring or tricyclic fused ring group which may have a substituent; Q2 represents a single bond, an oxygen atom, a sulfur atom, a linear or branched C1-6 alkylene group or the like; QA represents an arylalkenyl group which may have a substituent or a heteroarylalkenyl group which may have a substituent; and T1 represents a carbonyl group or the like] and a medicament comprising the same. The compound has strong FXa inhibitory action, provides prompt, sufficient and long-lasting anti-thrombus effects when orally administered, and has low side effects and is therefore useful as an excellent anticoagulant.Type: GrantFiled: February 12, 2001Date of Patent: June 8, 2004Assignee: Daiichi Pharmaceutical Co., Ltd.Inventors: Syozo Kobayashi, Satoshi Komoriya, Noriyasu Haginoya, Masanori Suzuki, Toshiharu Yoshino, Takayasu Nagahara, Tsutomu Nagata, Haruhiko Horino, Masayuki Ito, Akiyoshi Mochizuki
-
Publication number: 20040082611Abstract: Described in the present invention are a sulfonyl derivative represented by the following formula (I):Type: ApplicationFiled: October 9, 2003Publication date: April 29, 2004Applicant: DAIICHI PHARMACEUTICAL CO., LTD.Inventors: Syozo Kobayashi, Satoshi Komoriya, Noriyasu Haginoya, Masanori Suzuki, Toshiharu Yoshino, Takayasu Nagahara, Tsutomu Nagata, Haruhiko Horino, Masayuki Ito, Akiyoshi Mochizuki
-
Publication number: 20040077709Abstract: The present invention relates to neuronal death inhibitors containing, as its active ingredient, a compound represented by the following formula (1): 1Type: ApplicationFiled: October 14, 2003Publication date: April 22, 2004Applicant: DAIICHI PHARMACEUTICAL CO., LTD.Inventors: Yoshiya Murashima, Shigeo Watabe, Mitsunobu Yoshii
-
Patent number: 6689798Abstract: The present invention provides novel benzofuran derivatives represented by the following formula (I) or salts thereof: wherein Py is a 2-, 3-, or 4-pyridyl group and R is a substituted or unsubstituted phenyl group or a substituted or unsubstituted aromatic heterocyclic group. The present invention also relates to inhibitors of steroid 17&agr;-hydroxylase and/or steroid C17-20 lyase and pharmaceutical compositions containing a benzofuran derivative of the above formula (I), or the salt.Type: GrantFiled: November 18, 2002Date of Patent: February 10, 2004Assignee: Daiichi Pharmaceutical Co., Ltd.Inventors: Shin'ichi Shimada, Shin Nomoto, Masayuki Okue, Ken'ichi Kimura, Junji Nakamura, Yoshikazu Ikeda, Takeko Takada
-
Patent number: 6677456Abstract: This invention is to provide a novel taxol derivative useful as an antitumor compound having respective substituent groups, represented by the following formula (I) which can be orally administeredType: GrantFiled: March 6, 2002Date of Patent: January 13, 2004Assignee: Daiichi Pharmaceutical Co., Ltd.Inventors: Tsunehiko Soga, Kouichi Uoto, Yasuyuki Takeda
-
Publication number: 20030236191Abstract: The present invention provides an agent for preventing and/or treating cachesia comprising TCF-II as an effective ingredient. An excellent agent for preventing and treating cachexia caused by cancer, acquired immunodeficient syndrome (AIDS), cardiac diseases, infectious disease, shock, burn, endotoxinemia, organ inflammation, surgery, diabetes, collagen diseases, radiotherapy, chemotherapy is provided by the present invention and useful for medicine.Type: ApplicationFiled: March 5, 2003Publication date: December 25, 2003Applicant: Daiichi Pharmaceutical Co., Ltd.Inventors: Masamichi Kojiro, Hirohisa Yano, Akihiro Iemura
-
Publication number: 20030232808Abstract: Described is a sulfonyl derivative represented by the following formula (I): 1Type: ApplicationFiled: December 20, 2002Publication date: December 18, 2003Applicant: DAIICHI PHARMACEUTICAL CO., LTD.Inventors: Syozo Kobayashi, Satoshi Komoriya, Masayuki Ito, Tsutomu Nagata, Akiyoshi Mochizuki, Noriyasu Haginoya, Takayasu Nagahara, Haruhiko Horino
-
Patent number: 6656952Abstract: An antibacterial drug having potent antibacterial activities upon various bacteria including resistant strains and high safety is disclosed, which comprises as an active ingredient, quinolone derivatives represented by the following formula (I), its salts or hydrates thereof: wherein R1 represents a hydrogen atom or an alkyl group having 1 to 6 carbon atoms, R2 represents a halogenomethoxyl group or an alkoxyl group, R3 represents an alkyl group, an alkenyl group, a halogenoalkyl group, a cyclic alkyl group, a heteroaryl group, an alkoxyl group or an alkylamino group, and R4 represents a hydrogen atom, a phenyl group, an acetoxymethyl group, a pivaloyloxymethyl group, an ethoxycarbonyl group, a choline group, a dimethylaminoethyl group, a 5-indanyl group, a phthalidinyl group, a 5-alkyl-2-oxo-1,3-dioxol-4-ylmethyl group, 3-acetoxy-2-oxobutyl group, an alkyl group, an alkoxylmethyl group or a phenylalkyl group. These substituents may further have additional substituents.Type: GrantFiled: December 23, 1999Date of Patent: December 2, 2003Assignee: Daiichi Pharmaceutical Co., Ltd.Inventors: Makoto Takemura, Hisashi Takahashi, Hitoshi Ohki, Kenichi Kimura, Rie Miyauchi, Toshiyuki Takeda
-
Patent number: 6646123Abstract: The present invention relates to a novel taxol derivative having an antitumor activity which is represented by formula (1). [In the formula (I), R1: a phenyl group, R2: an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group or an alkoxyl group, R3: a hydrogen atom, a hydroxyl group, a halogen atom, an alkoxyl group, a group —O—R311 an acyloxy group or a group —O—CO—R31, (in which R31: an alkylamino group, an alkenyl group, an alkynyl group, a cycloalkyl group, an aryl group or a heterocyclic group), R4 and R5: a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group, an aryl group or a heterocyclic group, Z1: a hydrogen atom, a hydroxyl group, a halogen atom or an alkyl group, Z2: a hydrogen atom, a hydroxyl group, a halogen atom or an alkyl group, Z3: an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, an aryl group or a heterocyclic group].Type: GrantFiled: April 22, 2002Date of Patent: November 11, 2003Assignee: Daiichi Pharmaceutical Co., Ltd.Inventors: Hirofumi Terasawa, Tsunehiko Soga, Takashi Ishiyama
-
Publication number: 20030171262Abstract: A drug complex characterized in that a residue of a drug compound such as antineoplastic agents and a carboxy(C1-4)alkyldextran polyalcohol obtained by treating a dextran under conditions that enable substantially complete polyalcoholization are bound to each other by means of a spacer comprising an amino acid or a spacer comprising peptide-bonded 2 to 8 amino acids. Said complex is characterized in that it has excellent selectivity to tumorous sites so as to exhibit high antineoplastic activity and also achieves reduced appearance of toxicity.Type: ApplicationFiled: May 28, 2002Publication date: September 11, 2003Applicant: Daiichi Pharmaceutical Co., Ltd.Inventors: Kazuhiro Inoue, Hiroshi Susaki, Masahiro Ikeda, Hiroshi Kuga, Eiji Kumazawa, Akiko Togo
-
Publication number: 20030170240Abstract: The effects of endogenous insulin-like growth factor can be appreciated by administering compounds capable of increasing free IGF in living bodies. Compounds are described which can elevate the concentration of unbound IGF by converting endogenous IGF (insulin-like growth factor) into free, biologically active IGF or elevating the concentration of the complex of IGF and IGFBP (insulin-like growth factor binding protein) in living bodies. Medicaments can be prepared containing these compounds or these compounds may be used in methods for the prevention and or treatment of IGF-responsive diseases such as diabetes, amyotrophic lateral sclerosis, or osteoporosis.Type: ApplicationFiled: June 19, 2002Publication date: September 11, 2003Applicant: DAIICHI PHARMACEUTICAL CO., LTD.Inventors: Katsuichi Sakano, Nobuyuki Higashihashi, Ryuji Hashimoto
-
Patent number: 6613735Abstract: The present invention is directed to a composition for gene transfer which composition contains a quaternary ammonium salt represented by formula (1): (wherein each of R1, R2, R3, R4, and R5, which are identical to or different from one another, represents a C9-C17 aliphatic group); X1 represents a halogen atom; and n is an integer from 1 to 10 inclusive; and a method for introducing a gene into a cell by use of the composition. The composition enables effective delivery and expression of a gene which previously could not be effectively expressed in cells due to the low ratio at which the gene is delivered into cells. Therefore, the composition is advantageously used as a gene transfer reagent or a pharmaceutical.Type: GrantFiled: January 2, 2002Date of Patent: September 2, 2003Assignee: Daiichi Pharmaceutical Co., Ltd.Inventors: Kenichi Tanaka, Hiroshi Kikuchi, Norio Suzuki
-
Publication number: 20030162971Abstract: The present invention relates to a novel taxol derivative having an antitumor-activity which is represented by formula (1).Type: ApplicationFiled: April 22, 2002Publication date: August 28, 2003Applicant: DAIICHI PHARMACEUTICAL CO., LTD.Inventors: Hirofumi Terasawa, Tsunehiko Soga, Takashi Ishiyama
-
Publication number: 20030149079Abstract: The present invention provides novel benzofuran derivatives represented by the following formula (I) or salts thereof: 1Type: ApplicationFiled: November 18, 2002Publication date: August 7, 2003Applicant: Daiichi Pharmaceutical Co., Ltd.Inventors: Shin?apos;ichi Shimada, Shin Nomoto, Masayuki Okue, Ken?apos;ichi Kimura, Junji Nakamura, Yoshikazu Ikeda, Takeko Takada
-
Publication number: 20030138485Abstract: The present invention relates to a disintegrant comprising a substance which is solid at room temperature and has a water solubility of 30 wt. % or more, a saturated aqueous solution of the substance having a viscosity of 50 mPa·s.Type: ApplicationFiled: November 13, 2002Publication date: July 24, 2003Applicant: DAIICHI PHARMACEUTICAL CO., LTD.Inventors: Toshio Murakami, Noritaka Il, Hiroyuki Sakurai
-
Patent number: 6596706Abstract: The present invention relates to a compound represented by formula (1): wherein Q, which may have a substituent, represents an aryl group, a heterocyclic group, a diarylmethyl group, or an aralkyl group; R, which may have a substituent, represents a bicyclic nitrogen-containing heterocyclic group or a phenyl group; and Z represents a C1-C3 alkylene group, a C2-C4 alkenylene group, a C1-C3 alkylene group having one hydroxyl group, a carbonyl moiety, a C1-C2 alkylene group containing one carbonyl moiety at one end or an intermediate position of the carbon chain, or an oxalyl group; or salts thereof and a piperazine-cyclodextrin complex combined with a water-soluble cyclodextrin derivative. The complex exhibits enhanced water solubility, excellent stability, and low topical stimulation and is useful as a therapeutic agent for circulatory diseases and diseases of the brain region.Type: GrantFiled: May 8, 2000Date of Patent: July 22, 2003Assignee: Daiichi Pharmaceutical Co., Ltd.Inventors: Masahiko Kikuchi, Yukihiko Nagase, Kaneto Uekama